Cristina Dislich Ropke, CEO of Phytobios, a company that helps multinational and local companies turn Brazilian biodiversity into medicinal products, highlights the company’s exceptional perseverance in studying the Brazilian biodiversity at times when legal uncertainties threatened the development of this segment. She also expands on the drug development center founded in collaboration with the Brazilian Biosciences National Laboratory (LNBio), the company’s recent partnerships, and the role of Phytobios’ activities in environmental sustainability.
Could you tell our readers about Phytobios’ recent developments?
"Phytobios is responsible for the tough task of organising the expeditions to the Amazon and Atlantic forest and also to the Brazilian savannah for data and sample collection."
